EFMC-ACSMEDI MedChem Frontiers 2019

Joint Symposium on Medicinal Chemistry Frontiers

 Krakow, Poland    June 10-13, 2019

Plenary Speakers

First Time Disclosure
The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

Dr Yves P. AUBERSON
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland

Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT6 Receptor Ligands with Therapeutic Perspectives

Dr Jadwiga HANDZLIK
Dr Jadwiga HANDZLIK
MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland
Read more

Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders

Prof. Krzysztof  PALCZEWSKI
Prof. Krzysztof PALCZEWSKI
CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States
Read more

Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics

Dr Nurulain ZAVERI
Dr Nurulain ZAVERI
ASTRAEA THERAPEUTICS, Mountain View, United States
Read more

Matrix Metallo-Proteinases

Unnatural Amino Acids as a Tool for Better Understanding of Endoproteases Substrate Specificity

Prof. Marcin DRAG
Prof. Marcin DRAG
WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland
Read more

MMP-9 at the Synapse in the Brain and Mind

Prof. Leszek KACZMAREK
Prof. Leszek KACZMAREK
NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland
Read more

Target Identification by TAILS N-Terminal Positional Proteomics Leads to Development of a Pharmacological Molecular Corrector for Mutant MALT1 Impaired NF-kB Activation in Immunodeficiency

Prof. Christopher OVERALL
Prof. Christopher OVERALL
UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada
Read more

Chemical Biology Tools & Target Engagement Technologies

Chemical Physiology of Antibody Conjugates and Natural Products
"2018 MedChemComm Emerging Investigator Lectureship"

Dr Goncalo BERNARDES
Dr Goncalo BERNARDES
INSTITUTO DE MEDICINA MOLECULAR, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition

Dr Marc NAZARE
Dr Marc NAZARE
FMP, Berlin, Germany
Read more

Adventures in Targeting Protein Lipdation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology

Prof. Edward TATE
Prof. Edward TATE
IMPERIAL COLLEGE LONDON, London, United Kingdom
Read more

GPCRs: a Discovery Powerhouse

Design of Orexin-1 Receptor Selective Antagonists

Dr Uta LESSEL
Dr Uta LESSEL
BOEHRINGER INGELHEIM, Biberach an der Riss, Germany
Read more

Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases

Dr Lothar SCHWINK
Dr Lothar SCHWINK
SANOFI, Frankfurt Am Main, Germany
Read more

G Protein-Coupled Receptors: the Structural Basis for their Pharmacology

Dr Chris TATE
Dr Chris TATE
MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom
Read more

Genomics in Drug Discovery : Roles for Chemistry

Remedying the Diseased Genome with Precision-tailored Synthetic Gene Regulators (SynGRs)

Prof. Aseem ANSARI
Prof. Aseem ANSARI
UNIVERSITY OF WISCONSIN-MADISON, Madison, United States
Read more

Exploring Bacterial Genomes for Natural Product Discovery and Development

Prof. Alessandra S.  EUSTAQUIO
Prof. Alessandra S. EUSTAQUIO
UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States
Read more

Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway

Dr Mathias FREDERIKSEN
Dr Mathias FREDERIKSEN
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland

Specific and Multi-Targeted Drugs

Charting New Paths in Multi-Target Drug Discovery for Alzheimer’s Disease

Prof. Maria Laura BOLOGNESI
Prof. Maria Laura BOLOGNESI
UNIVERSITY OF BOLOGNA, Bologna, Italy
Read more

Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes

Dr Charlotte GRIFFITHS-JONES
Dr Charlotte GRIFFITHS-JONES
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom

Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor

Dr Sven RUF
Dr Sven RUF
SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany
Read more

Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element

Prof. Holger STARK
Prof. Holger STARK
HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany
Read more

Targeted Covalent Inhibitors

Mining the Protein Kinase Cysteinome

Dr Tjeerd BARF
Dr Tjeerd BARF
ACERTA PHARMA BV, Oss, The Netherlands
Read more

Safety First: Covalent Inhibitors from a Safety Perspective

Dr Mickael MOGEMARK
Dr Mickael MOGEMARK
ASTRAZENECA, Mölndal, Sweden
Read more

Adventures in Functional Assignment and Inhibition of Metallo-Enzymes

Prof. Christopher J. SCHOFIELD
Prof. Christopher J. SCHOFIELD
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Adding AI to the Drug Discovery Tool Box

Capturing and Applying Knowledge to Guide Compound Optimisation

Mr Nick FOSTER
Mr Nick FOSTER
OPTIBRIUM, Cambridge, United Kingdom
Read more

AI-based Chemical Synthesis for Accelerating Drug Discovery

Prof. Mark WALLER
Prof. Mark WALLER
UNIVERSITY OF WOLLONGONG, Wollongong, Australia
Read more

Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility

Dr Pat WALTERS
Dr Pat WALTERS
RELAY THERAPEUTICS, Cambridge, United States
Read more

Augmented Intelligence for Compound Design

Dr Michal WARCHOL
Dr Michal WARCHOL
ARDIGEN, Krakow, Poland
Read more

Advances in Protein Degradation Technologies

Targeted Protein Degradation with Small Molecules: how PROTACs Work

Prof. Alessio CIULLI
Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Read more

The Ubiquitin Proteasome System

Prof. Huib OVAA
Prof. Huib OVAA
LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands
Read more

Opioid, Pain, Endo-Cannabinoid

The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279

Prof. James BREITENBUCHER
Prof. James BREITENBUCHER
UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States
Read more

The Huge Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection

Prof. Rafael FRANCO
Prof. Rafael FRANCO
UNIVERSITY OF BARCELONA, Barcelona, Spain
Read more

Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint

Prof. Katarzyna STAROWICZ-BUBAK
Prof. Katarzyna STAROWICZ-BUBAK
INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland
Read more

Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain

Dr Dominique SURLERAUX
Dr Dominique SURLERAUX
BCI PHARMA, Liège, Belgium
Read more